Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease

Journal of Clinical Investigation

Volumn 98, Issue 5, 1996, Pages 1107-1113

  Wu, Jianguo ^a   Wilson, James ^b   He, Jin ^a   Xiang, Lianbin ^b   Schur, Peter H ^c   Mountz, John D ^a,d  

^a University of Alabama at Birmingham   (United States)

^b G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

apoptosis; autoimmunity; Fas ligand; single stranded conformational polymorphism; systemic lupus erythematosus

Indexed keywords

ADULT; APOPTOSIS; ARTICLE; CASE REPORT; CELL DEATH; CLINICAL FEATURE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0029737324     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118892     Document Type: Article

References (38)

1. Eisenberg, R.A., and P.L. Cohen. 1991. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243-269.
2. Watanabe-Fukunaga, R., C.I. Brannan, N.G. Copeland, N.A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (Lond.) 356:314-317.
3. Takahashi, T., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969-976.
4. Lynch, D., M. Watson, M.R. Alderson, P.R. Baum, R.E. Miller, T. Tough, M. Gibson, T. Davis-Smith, C.A. Smith, K. Hunter, et al. 1994. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1:131-136.
5. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1169-1178.
6. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science (Wash. DC). 267:1449-1456.
7. Fisher, G.H., F.J. Rosenberg, S.E. Straus, J.K. Dale, L.A. Middleton, A.Y. Lin, W. Strober, M.J. Lenardo, and J.M. Puck. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:935-946.
8. Rieux-Laucat, F., F. Le Deist, C. Hivroz, I.A. Roberts, K.M. Debatin, A. Fischer, and J.P. de Villartay. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science (Wash. DC). 268: 1347-1349.
9. Ju, S.T., D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D.H. Sherr, B.Z. Stanger, and A. Marshak-Rolhstein. 1995. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (Lond.). 373:444-448.
10. Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, and C.F. Ware. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (Lond.). 373:441-444.
11. Dhein, J., H. Walczak, C. Baumler, K.M. Debatin, and P.H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature (Lond.). 373:438-441.
12. Alderson, M.R., T.W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K.A. Schooley, R.G. Goodwin, C.A. Smith, F. Ramsdell, and D.H. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:71-77.
13. Kabelitz, D., T. Pohl, and K. Pechhold. 1993. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol. Today. 14: 339-340.
14. Green, D.R., and D.W. Scott. 1994. Activation-induced apoptosis in lymphocytes. Curr. Opin. Immunol. 6:476-187.
15. Amasaki, Y., S. Kobayashi, T. Takeda, N. Ogura, S. Jodo, T. Nakabayashi, A. Tsutsumi, A. Fujisaku, and T. Koike. 1995. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin. Exp. Immunol. 99:245-250.
16. Mysler, E., P. Bini, J. Drappa, P. Ramos, S.M. Friedman, P.H. Krammer, and K.B. Elkon. 1994. The apoptosis-1/Fas protein in human systemic lupus crythematosus. J. Clin. Invest. 93:1029-1034.
17. Cheng, J., T. Zhou, C. Liu, J.P. Shapiro, M.J. Brauer, M.C. Kiefer, P.J. Barr, and J.D. Mountz. 1994. Protection from Fas-mediated apoptosis by a soluble form of the fas molecule. Science (Wash. DC). 263:1759-1762.
18. Mountz, J.D., M.C. Pierson, T. Zhou, J. Cheng, K.B. Elkon, T. Hasunuma, K. Nishioka, K. Okumura, A. Lin, G.G. Song, J.K. Dale, M. Gourley, and S.E. Straus. 1995. sFas expression in patients with autoimmune disease. Arthritis Rheum. 38(S174):127. (Abstr.)
19. Papo, T., M. Ortova, J.-C. Piette, C. Frances, B. Autran, and G. Gorochov. 1995. High expression of soluble Fas by mononuclear cells of systemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (PAPS) patients. Arthritis Rheum. 38:S210. (Abstr.)
20. Knipping, E., P.H. Krammer, K.B. Onel, T.J.A. Lehman, E. Myler, and K.B. Elkon. 1995. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum. 38:1735-1737.
21. Goel, N., D.T. Ulrich, E.W. St. Clair, J.A. Fleming, D.H. Lynch, and M.F. Seldin. 1995. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum. 38:1738-1743.
22. Tan, E.M., A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F. Rothfield, J.G. Schaller, N. Talal, and R.J. Winchester. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271-1277.
23. Ushijima, T., Y. Hosoya, T. Suzuki, T. Sofuni, T. Sugimura, and M. Nagao. 1995. A rapid method for detection of mutations in the lac1 gene using PCR-single strand conformation polymorphism analysis: demonstration of its high sensitivity. Mutat. Res. 334:283-292.
24. Sawada, S., M. Honda, and M. Niimura. 1994. Molecular genetic analysis of the von Recklinghausen neurofibromatosis (NF1) gene using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) method. J. Dermatol (Tokyo). 21:294-300.
25. Mok, S.C., K.W. Lo, and S.W. Tsao. 1993. Direct cycle sequencing of mutated alleles detected by PCR single-strand conformation polymorphism analysis. Biotechniques. 14:790-794.
26. Schmid, C., H. Uittenbogaart, and J. V. Giorgi. 1994. Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. Cytometry. 15:12-20.
27. Takahashi, T., M. Tanaka, J. Inazawa, T. Abe, and S. Nagata. 1994. Human Fas ligand: gene structure, chromosomal location and species specificity. Intl. Immunol. 6:1564-1574.
28. Shimadzu, M., H. Nunoi, H. Terasaki, R. Ninomiya, M. Iwata, S. Kanegasaka, and I. Matsuda. 1995. Structural organization of the gene for CD40 ligand: molecular analysis for diagnosis of X-linked hyper-IgM syndrome. Biochim. Biophys. Acta. 1260:67-72.
29. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO (Eur. Mol. Biol. Organ.) J. 14:1129-1135.
30. Stanger, B.Z., P. Leder, T.H. Lee, E. Kim, and B. Seed. 1995. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 81:513-523.
31. Chinnaiyan, A.M., K. O'Rourke, M. Tewari, and V.M. Dixit. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 81:505-512.
32. Boldin, M.P., E.E. Varfolomeev, Z. Pancer, I.L. Mett, J.H. Camonis, and D. Wallach. 1995. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270:7795-7798.
33. Steinberg, A.D. 1994. Systemic lupus erythematosus: theories of pathogenesis and approach to therapy. Clin. Immunol. Immunopathol. 72:171-176.
34. Elkon, K.B. 1994. Apoptosis in SLE - too little or too much? Clinical & Experimental Rheumatology. 12:553-559.
35. Mountz, J.D., J. Wu, J. Cheng, and T. Zhou. 1994. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum. 37:1415-1420.
36. Rose, L.M., D.S. Latchman, and D.A. Isenberg. 1994. Bcl-2 and Fas, molecules which influence apoptosis. A possible role in systemic lupus erythematosus? Autoimmunity. 17:271-278.
37. Ohsako, S., M. Hara, M. Harigai, C. Fukasawa, and S. Kashiwazaki. 1994. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin. Immunol. Immunopathol. 73:109-114.
38. Kovacs, B., T. Szentendrei, J.M. Bednarek, M.C. Pierson, J.D. Mountz, S.A. Vogelgasang, and G.C. Tsokos. 1996. Persistent expression of a soluble form of Fax/APO1 in continuously activated T-cells from a patient with SLE. Clin. Exp. Immuno. In Press.